News Agency
The Times

CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

  • Written by PR Newswire
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced the 2022 Interim Results.

Business Highlights

  • CT053: completed enrollment for pivotal Phase II trial in China,...

Read more: CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

Commercial Leasing Mistakes That Can Cost Your Business

Signing a commercial lease is a significant commitment, and the mistakes made at the outset of a tenancy can follow a business for the entire duration of the agreement. Many tenants enter lease negotiations without a full understanding of what... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion